Kirkland Represents Bristol Myers Squibb on Acquisition of MyoKardia for $13.1 Billion

Kirkland advised Bristol Myers Squibb (NYSE: BMY), a global biopharmaceutical company, on its agreement to acquire MyoKardia, a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, for $13.1 billion. Through the transaction, Bristol Myers Squibb gains mavacamten, a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy, a chronic heart disease with high morbidity and patient impact. The transaction is subject to customary closing conditions and is expected to close during the fourth quarter of 2020.   

Read the Bristol Myers Squibb press release

The Kirkland team was led by transactional partners Maggie Flores, Jonathan Davis and Daniel Wolf, capital markets partner Sophia Hudson, executive compensation partners Scott Price and Kate Coverdale, antitrust partners Matt Reilly and Jeffrey Ayer, technology & IP transactions partner Lisa Samenfeld, and intellectual property partner Patricia Carson.